Skip to Content

Grifols SA ADR GRFS Stock Quote

| Rating as of


Last close prices updated as of Jan 30, 2023, 4:14 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 9.23
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Mid Growth
  • Day Range 8.96  –  9.16
  • Year Range 5.71  –  13.34
  • Market Cap 6.1170 Bil
  • Volume / Avg 331,415.0 /  1.1 Mil
  • Price / Sales 1.11
  • Price / Book 0.91
  • Forward Div Yield
  • Trailing Div Yield 5.07%

Morningstar‘s Stock Analysis GRFS

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Despite Weaker Near-Term Profitability With COVID-19 Recovery, Grifols Holds a Narrow Moat in Plasma

Karen Andersen Sector Strategist

Business Strategy and Outlook

| Karen Andersen |

Market share in the global plasma-derived protein business is concentrated among a small number of global players. Grifols lifted itself to the level of competitors Takeda and CSL with the $3.7 billion acquisition of Talecris in 2011. Over the past several years, the firm has been fighting competition and coronavirus pandemic headwinds with acquisitions and investments to build plasma collection and fractionation capacity, support its portfolio and pipeline, and expand geographically.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics GRFS

Company Profile GRFS

Business Description

As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 77% of sales in 2021. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue (following the Biotest acquisition).

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles
Barcelona, 08174, ESP
Industry Drug Manufacturers - General
Employees 27,000

Related Articles GRFS

FAQs for Grifols SA ADR Stock

No. GRFS does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

GRFS’s market cap is 6.12 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

GRFS’s stock style is Mid Growth.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

GRFS’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare GRFS’s historical performance against its industry peers and the overall market.